← Back to patent-cliff list
CAS 123-08-0
4-hydroxybenzaldehyde4-Formylphenol4-Hydroxybenzaldehyde
Codes: PIMAV-001, Tamsulosin Hydrochloride-022, SAFI-002, BAZE-010, PIOG-015, Bisoprolol-015, FEBU-016, HYPIL-006
Application context (from source-drug indications)
DelusionPimavanserin TartrateHallucinationPimavanserin TartrateErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinParkinson's diseaseSafinamide MesylatePainSafinamide MesylateDrug-induced dyskinesiaSafinamide MesylateHepatic function declineSafinamide MesylateMultiple system atrophySafinamide MesylateRenal impairmentSafinamide MesylateLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideOestrogen deficiency syndromeConjugated Estrogens/Bazedoxifene AcetateOsteoporosisConjugated Estrogens/Bazedoxifene AcetateVasomotor symptomsConjugated Estrogens/Bazedoxifene AcetateNon-invasive ductal carcinomaConjugated Estrogens/Bazedoxifene AcetateAnxietyConjugated Estrogens/Bazedoxifene AcetateMenopausal symptomsConjugated Estrogens/Bazedoxifene AcetateType 2 diabetesAlogliptin Benzoate/Pioglitazone HydrochlorideBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideHypertensionAmlodipine Besylate/Bisoprolol FumarateEssential hypertensionAmlodipine Besylate/Bisoprolol FumarateHyperuricaemiaFebuxostatGoutFebuxostatIntracranial haemorrhageFebuxostatUlcerative colitisFebuxostatChronic renal impairmentFebuxostatPainFebuxostatBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochloridePostmenopausal osteoporosisBazedoxifene AcetateBreast cancerBazedoxifene AcetateOsteoporosisBazedoxifene AcetateMenopausal symptomsBazedoxifene AcetateType 2 diabetesPioglitazone HydrochloridePulmonary hypertensionPioglitazone HydrochlorideBreast cancerPioglitazone HydrochlorideNon-alcoholic steatohepatitisPioglitazone HydrochlorideCocaine addictionPioglitazone HydrochlorideAlcohol abusePioglitazone HydrochlorideHypertensionBisoprolol FumarateAngina pectorisBisoprolol FumarateChronic obstructive pulmonary diseaseBisoprolol FumarateCardiac and vascular disordersBisoprolol FumarateAcute coronary syndromeBisoprolol FumarateFastingBisoprolol Fumarate肾上腺脑白质营养不良LeriglitazoneFriedreich's ataxiaLeriglitazone
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Pimavanserin Tartrate | Tier C — Watch / trade | 2029 |
| Tadalafil/Tamsulosin | Tier C — Watch / trade | - |
| Safinamide Mesylate | Tier C — Watch / trade | - |
| Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Conjugated Estrogens/Bazedoxifene Acetate | Tier C — Watch / trade | - |
| Alogliptin Benzoate/Pioglitazone Hydrochloride | Tier C — Watch / trade | - |
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Amlodipine Besylate/Bisoprolol Fumarate | Tier C — Watch / trade | - |
| Febuxostat | Tier C — Watch / trade | - |
| Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Bazedoxifene Acetate | Tier C — Watch / trade | - |
| Pioglitazone Hydrochloride | Tier B — Position early | - |
| Bisoprolol Fumarate | Tier C — Watch / trade | - |
| Leriglitazone | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-hydroxybenzaldehyde→1-bromo-2-methylpropane→4-isobutoxybenzaldehyde→(E)-4-isobutoxybenzaldehyde oxime→(4-isobutoxyphenyl)methanamine→1-isobutoxy-4-(isocyanatomethyl)benzene→N-(4-fluorobenzyl)-1-methylpiperidin-4-amine→1-methylpiperidin-4-one→(4-fluorophenyl)methanamine→sodium triacetoxyhydroborate
5-(2(R)-Aminopropyl)-2-methoxybenzenesulfonamide→Benzaldehyde→4-Methoxybenzaldehyde→4-Formylphenol→(4-Fluorophenyl)methanone→2-methoxy-5-[(2R)-2-[(E)-(phenylmethylidene)amino]propyl]benzene-1-sulfonamide→2-Methoxy-5-[(2R)-2-[(E)-[(4-methoxyphenyl)methylidene]amino]propyl]benzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Hydroxyphenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Fluorophenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→1-ethoxy-2-(2-iodoethoxy)benzene→(E)-[2-(2-ethoxyphenoxy)ethyl][(2R)-1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl](phenylmethylidene)azanium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-methoxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-hydroxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-fluorophenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(-)-5-[2(R)-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
Solifenacin Succinate/Tamsulosin HydrochlorideOptimised routesteps: 4total yield: 18g(Tamsulosin Hydrochloride (API))
5-(2(R)-Aminopropyl)-2-methoxybenzenesulfonamide→Benzaldehyde→4-Methoxybenzaldehyde→4-Formylphenol→(4-Fluorophenyl)methanone→2-methoxy-5-[(2R)-2-[(E)-(phenylmethylidene)amino]propyl]benzene-1-sulfonamide→2-Methoxy-5-[(2R)-2-[(E)-[(4-methoxyphenyl)methylidene]amino]propyl]benzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Hydroxyphenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→5-[(2R)-2-[(E)-[(4-Fluorophenyl)methylidene]amino]propyl]-2-methoxybenzene-1-sulfonamide→1-ethoxy-2-(2-iodoethoxy)benzene→(E)-[2-(2-ethoxyphenoxy)ethyl][(2R)-1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl](phenylmethylidene)azanium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-methoxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-hydroxyphenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(2R)-N-[2-(2-Ethoxyphenoxy)ethyl]-N-[(E)-(4-fluorophenyl)methylidene]-1-(4-methoxy-3-sulfamoylphenyl)propan-2-iminium iodide→(-)-5-[2(R)-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-(benzyloxy)-2-(4-(benzyloxy)phenyl)-3-methyl-1H-indole→1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-5-(benzyloxy)-2-(4-(benzyloxy)phenyl)-3-methyl-1H-indole→4-hydroxybenzaldehyde→1-(2-chloroethyl)azepane hydrochloride→4-(2-(azepan-1-yl)ethoxy)benzaldehyde→(4-(2-(azepan-1-yl)ethoxy)phenyl)methanol→1-(2-(4-(chloromethyl)phenoxy)ethyl)azepane hydrochloride
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | Ethyl 2-(3-Formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.